Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023 01 05; 25(1):4-25.
View in:
PubMed
A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer. Clin Cancer Res. 2022 11 01; 28(21):4689-4701.
View in:
PubMed
Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Invest. 2022 09 15; 132(18).
View in:
PubMed
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell. 2022 09 12; 40(9):939-956.e16.
View in:
PubMed
Mitochondrial remodeling and ischemic protection by G protein-coupled receptor 35 agonists. Science. 2022 08 05; 377(6606):621-629.
View in:
PubMed
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proc Natl Acad Sci U S A. 2022 04 05; 119(14):e2120403119.
View in:
PubMed
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clin Cancer Res. 2022 03 01; 28(5):831-839.
View in:
PubMed
THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE. Trans Am Clin Climatol Assoc. 2022; 132:170-181.
View in:
PubMed
David M. Livingston (1941-2021). Cell. 2021 12 09; 184(25):6007-6009.
View in:
PubMed
Belzutifan, a Potent HIF2a Inhibitor, in the Pacak-Zhuang Syndrome. N Engl J Med. 2021 11 25; 385(22):2059-2065.
View in:
PubMed
Targeting oncoproteins with a positive selection assay for protein degraders. Sci Adv. 2021 02; 7(6).
View in:
PubMed
Author Correction: Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Res. 2021 Jan; 31(1):104.
View in:
PubMed
2-Oxoglutarate-dependent dioxygenases in cancer. Nat Rev Cancer. 2020 12; 20(12):710-726.
View in:
PubMed
Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 2020 10; 26(10):1519-1530.
View in:
PubMed
Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Res. 2021 01; 31(1):80-93.
View in:
PubMed
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell. 2020 01 13; 37(1):37-54.e9.
View in:
PubMed
Leveraging insights into cancer metabolism-a symposium report. Ann N Y Acad Sci. 2020 02; 1462(1):5-13.
View in:
PubMed
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes Dev. 2019 12 01; 33(23-24):1718-1738.
View in:
PubMed
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. Sci Signal. 2019 10 01; 12(601).
View in:
PubMed
Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma. JCI Insight. 2019 08 08; 4(15).
View in:
PubMed
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance. Proc Natl Acad Sci U S A. 2019 08 20; 116(34):16997-17006.
View in:
PubMed
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science. 2019 03 15; 363(6432):1217-1222.
View in:
PubMed
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell Metab. 2019 05 07; 29(5):1166-1181.e6.
View in:
PubMed
Peptidic degron for IMiD-induced degradation of heterologous proteins. Proc Natl Acad Sci U S A. 2019 02 12; 116(7):2539-2544.
View in:
PubMed
Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov. 2019 02; 9(2):230-247.
View in:
PubMed
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1a activation. Proc Natl Acad Sci U S A. 2018 10 09; 115(41):E9600-E9609.
View in:
PubMed
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. 2018 09 20; 175(1):101-116.e25.
View in:
PubMed
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018 07 20; 361(6399):290-295.
View in:
PubMed
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. Proc Natl Acad Sci U S A. 2018 04 17; 115(16):E3741-E3748.
View in:
PubMed
HIF2 Inhibitor Joins the Kidney Cancer Armamentarium. J Clin Oncol. 2018 03 20; 36(9):908-910.
View in:
PubMed
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018 Feb 16; 359(6377):801-806.
View in:
PubMed
Senator McCain and Our Shared Humanity. Am J Med. 2018 03; 131(3):216-217.
View in:
PubMed
Climate Change: What Would Lincoln Do? JAMA. 2017 Aug 15; 318(7):611.
View in:
PubMed
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Sci Transl Med. 2017 07 12; 9(398).
View in:
PubMed
The EGLN-HIF O2-Sensing System: Multiple Inputs and Feedbacks. Mol Cell. 2017 Jun 15; 66(6):772-779.
View in:
PubMed
Publish houses of brick, not mansions of straw. Nature. 2017 05 23; 545(7655):387.
View in:
PubMed
Common pitfalls in preclinical cancer target validation. Nat Rev Cancer. 2017 07; 17(7):425-440.
View in:
PubMed
Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma. Proc Natl Acad Sci U S A. 2017 01 31; 114(5):1027-1032.
View in:
PubMed
The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. Trans Am Clin Climatol Assoc. 2017; 128:298-307.
View in:
PubMed
Targeting HIF2 in Clear Cell Renal Cell Carcinoma. Cold Spring Harb Symp Quant Biol. 2016; 81:113-121.
View in:
PubMed
Pathways for Oxygen Regulation and Homeostasis: The 2016 Albert Lasker Basic Medical Research Award. JAMA. 2016 Sep 27; 316(12):1252-3.
View in:
PubMed
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2. Mol Cell. 2016 09 15; 63(6):1006-20.
View in:
PubMed
On-target efficacy of a HIF-2a antagonist in preclinical kidney cancer models. Nature. 2016 11 03; 539(7627):107-111.
View in:
PubMed
pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science. 2016 08 26; 353(6302):929-32.
View in:
PubMed
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. Cell. 2016 Jun 30; 166(1):126-39.
View in:
PubMed
EGLN1 Inhibition and Rerouting of a-Ketoglutarate Suffice for Remote Ischemic Protection. Cell. 2016 Apr 07; 165(2):497.
View in:
PubMed
EGLN1 Inhibition and Rerouting of a-Ketoglutarate Suffice for Remote Ischemic Protection. Cell. 2016 Feb 25; 164(5):884-95.
View in:
PubMed
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. J Biol Chem. 2016 Feb 19; 291(8):4256-65.
View in:
PubMed
Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21. Proc Natl Acad Sci U S A. 2015 Dec 15; 112(50):15372-7.
View in:
PubMed
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res. 2016 Apr 01; 22(7):1632-41.
View in:
PubMed
EglN2 associates with the NRF1-PGC1a complex and controls mitochondrial function in breast cancer. EMBO J. 2015 Dec 02; 34(23):2953-70.
View in:
PubMed
Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle. Proc Natl Acad Sci U S A. 2015 Sep 15; 112(37):11642-7.
View in:
PubMed
DisABLing kidney cancers caused by fumarate hydratase mutations. Cancer Cell. 2014 Dec 08; 26(6):779-780.
View in:
PubMed
Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. Cancer Res. 2014 Nov 15; 74(22):6554-64.
View in:
PubMed
A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet. 2014 Sep; 46(9):951-6.
View in:
PubMed
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell. 2014 Aug 11; 26(2):222-34.
View in:
PubMed
Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev. 2014 Jul 01; 28(13):1429-44.
View in:
PubMed
A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014 Aug; 25(8):1603-8.
View in:
PubMed
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. 2014 Mar 01; 28(5):479-90.
View in:
PubMed
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell. 2013 Dec 09; 24(6):738-50.
View in:
PubMed
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014 Jan 17; 343(6168):305-9.
View in:
PubMed
Twenty-fifth annual Pezcoller Symposium: Metabolism and tumorigenesis. Cancer Res. 2013 Oct 15; 73(20):6124-7.
View in:
PubMed
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
View in:
PubMed
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013 Apr 15; 27(8):836-52.
View in:
PubMed
Influence of metabolism on epigenetics and disease. Cell. 2013 Mar 28; 153(1):56-69.
View in:
PubMed
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013 Mar 29; 339(6127):1621-5.
View in:
PubMed
Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation. Proc Natl Acad Sci U S A. 2012 Nov 06; 109(45):18499-504.
View in:
PubMed
Molecular biology. Use and abuse of RNAi to study mammalian gene function. Science. 2012 Jul 27; 337(6093):421-2.
View in:
PubMed
The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013 Feb; 23(1):18-25.
View in:
PubMed
Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood. 2012 Aug 30; 120(9):1916-22.
View in:
PubMed
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012 Feb 15; 483(7390):484-8.
View in:
PubMed
Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol. 2011; 76:335-45.
View in:
PubMed
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968.
View in:
PubMed
New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am. 2011 Aug; 25(4):667-86.
View in:
PubMed
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A. 2011 Aug 16; 108(33):13379-86.
View in:
PubMed
Genetic and functional studies implicate HIF1a as a 14q kidney cancer suppressor gene. Cancer Discov. 2011 Aug; 1(3):222-35.
View in:
PubMed
Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma. Clin Genet. 2011 Jun; 79(6):539-45.
View in:
PubMed
Good COP1 or bad COP1? In vivo veritas. J Clin Invest. 2011 Apr; 121(4):1263-5.
View in:
PubMed
Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer. 2011 Feb; 18(1):73-83.
View in:
PubMed
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell. 2010 Nov 16; 18(5):472-84.
View in:
PubMed
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Ann N Y Acad Sci. 2010 Oct; 1210:1-7.
View in:
PubMed
Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. 2010 Sep 07; 122(10):1004-16.
View in:
PubMed
Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell. 2010 Aug 09; 18(2):147-59.
View in:
PubMed
Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. 2010 Jul 23; 329(5990):407.
View in:
PubMed
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report. J Neurooncol. 2011 Jan; 101(2):307-10.
View in:
PubMed
Q&A: Cancer: clues from cell metabolism. Nature. 2010 Jun 03; 465(7298):562-4.
View in:
PubMed
Prostate cancer: beta control your hormones. Cancer Cell. 2010 Apr 13; 17(4):311-2.
View in:
PubMed
Slaying RAS with a synthetic lethal weapon. Cell Res. 2010 Feb; 20(2):119-21.
View in:
PubMed
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009 Nov 06; 16(5):413-24.
View in:
PubMed
Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med. 2009 Oct 27; 1(10):99.
View in:
PubMed
SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling. Cancer Cell. 2009 Sep 08; 16(3):180-2.
View in:
PubMed
A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol. 2009 Nov; 29(21):5729-41.
View in:
PubMed
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest. 2009 Aug; 119(8):2160-70.
View in:
PubMed
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009 Jun 01; 69(11):4674-81.
View in:
PubMed
Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer. 2009 May 15; 115(10 Suppl):2262-72.
View in:
PubMed
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer. 2009 May 15; 115(10 Suppl):2247-51.
View in:
PubMed
Kidney cancer: now available in a new flavor. Cancer Cell. 2008 Dec 09; 14(6):423-4.
View in:
PubMed
A role for mammalian Sin3 in permanent gene silencing. Mol Cell. 2008 Nov 07; 32(3):359-70.
View in:
PubMed
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A. 2008 Oct 28; 105(43):16484-9.
View in:
PubMed
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008 Nov; 8(11):865-73.
View in:
PubMed
Senescence triggered by the loss of the VHL tumor suppressor. Cell Cycle. 2008 Jun 15; 7(12):1709-12.
View in:
PubMed
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008 May 23; 30(4):393-402.
View in:
PubMed
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 01; 22(7):884-93.
View in:
PubMed
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 2008 Mar; 10(3):361-9.
View in:
PubMed
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood. 2008 Mar 15; 111(6):3236-44.
View in:
PubMed
Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer. Cancer Res. 2007 Dec 01; 67(23):11102-5.
View in:
PubMed
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell. 2007 Oct 12; 28(1):15-27.
View in:
PubMed
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol. 2007 Aug; 27(15):5381-92.
View in:
PubMed
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell. 2007 Mar 09; 128(5):889-900.
View in:
PubMed
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):667s-670s.
View in:
PubMed
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):680s-684s.
View in:
PubMed
The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol. 2007 Mar; 27(6):2092-102.
View in:
PubMed
Von Hippel-Lindau disease. Annu Rev Pathol. 2007; 2:145-73.
View in:
PubMed
The von hippel-lindau tumor suppressor protein: an update. Methods Enzymol. 2007; 435:371-83.
View in:
PubMed
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol. 2007 Feb; 9(2):225-32.
View in:
PubMed
Molecular pathways in renal cell carcinoma--rationale for targeted treatment. Semin Oncol. 2006 Oct; 33(5):588-95.
View in:
PubMed
Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J. 2006 Oct 04; 25(19):4650-62.
View in:
PubMed
Cell biology: divining cancer cell weaknesses. Nature. 2006 May 04; 441(7089):32-4.
View in:
PubMed
Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol. 2006 Feb; 168(2):574-84.
View in:
PubMed
Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma. Endocr Pathol. 2006; 17(2):97-106.
View in:
PubMed
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A. 2006 Jan 03; 103(1):105-10.
View in:
PubMed
The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005 Sep; 5(9):689-98.
View in:
PubMed
The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun. 2005 Dec 09; 338(1):627-38.
View in:
PubMed
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005 Aug; 8(2):155-67.
View in:
PubMed
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. 2005 Jul; 8(1):25-33.
View in:
PubMed
Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell. 2005 Jun 10; 18(6):623-35.
View in:
PubMed
ROS: really involved in oxygen sensing. Cell Metab. 2005 Jun; 1(6):357-8.
View in:
PubMed
Bioluminescent imaging of ubiquitin ligase activity: measuring Cdk2 activity in vivo through changes in p27 turnover. Methods Enzymol. 2005; 399:530-49.
View in:
PubMed
The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harb Symp Quant Biol. 2005; 70:159-66.
View in:
PubMed
Proline hydroxylation and gene expression. Annu Rev Biochem. 2005; 74:115-28.
View in:
PubMed
Role of VHL gene mutation in human cancer. J Clin Oncol. 2004 Dec 15; 22(24):4991-5004.
View in:
PubMed
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A. 2004 Nov 30; 101(48):16768-73.
View in:
PubMed
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004 Dec 01; 18(23):2893-904.
View in:
PubMed
The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6290S-5S.
View in:
PubMed
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S.
View in:
PubMed
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell. 2004 Jul; 6(1):7-10.
View in:
PubMed
Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med. 2004 Jun; 10(6):643-8.
View in:
PubMed
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Res. 2004 May 01; 64(9):3350-6.
View in:
PubMed
Fifteenth annual Pezcoller symposium: molecular in vivo visualization of cancer cells. Cancer Res. 2004 Apr 15; 64(8):2929-33.
View in:
PubMed
pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol. 2004 Apr; 24(8):3251-61.
View in:
PubMed
Gleevec: prototype or outlier? Sci STKE. 2004 Mar 16; 2004(225):pe12.
View in:
PubMed
Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature. 2004 Mar 11; 428(6979):194-8.
View in:
PubMed
Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of oxygen sensing. Methods Enzymol. 2004; 381:320-35.
View in:
PubMed
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003 Dec; 1(3):E83.
View in:
PubMed
The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol. 2003 Nov; 14(11):2703-11.
View in:
PubMed
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging. 2003 Oct; 2(4):297-302.
View in:
PubMed
TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003 Aug; 4(2):147-58.
View in:
PubMed
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med. 2003 Jul 31; 349(5):419-21.
View in:
PubMed
E2F1 as a target: promoter-driven suicide and small molecule modulators. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S48-54.
View in:
PubMed
Chemosensitivity linked to p73 function. Cancer Cell. 2003 Apr; 3(4):403-10.
View in:
PubMed
Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res. 2003 Apr; 1(6):453-62.
View in:
PubMed
HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest. 2003 Mar; 111(6):779-83.
View in:
PubMed
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev. 2003 Feb; 13(1):55-60.
View in:
PubMed
VHL and kidney cancer. Methods Mol Biol. 2003; 222:167-83.
View in:
PubMed
Detection of peptides, proteins, and drugs that selectively interact with protein targets. Genome Res. 2002 Nov; 12(11):1785-91.
View in:
PubMed
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A. 2002 Oct 15; 99(21):13459-64.
View in:
PubMed
Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology. 2002 Sep; 109(9):1745-51.
View in:
PubMed
Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002 Sep; 2(9):673-82.
View in:
PubMed
Using cancer genetics to guide the selection of anticancer drug targets. Curr Opin Pharmacol. 2002 Aug; 2(4):366-73.
View in:
PubMed
How oxygen makes its presence felt. Genes Dev. 2002 Jun 15; 16(12):1441-5.
View in:
PubMed
Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science. 2002 Jun 07; 296(5574):1886-9.
View in:
PubMed
The human p73 promoter: characterization and identification of functional E2F binding sites. Neoplasia. 2002 May-Jun; 4(3):195-203.
View in:
PubMed
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002 Apr; 1(3):237-46.
View in:
PubMed
Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol. 2002 Mar; 22(6):1947-60.
View in:
PubMed
An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep. 2002 Feb; 3(2):177-82.
View in:
PubMed
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 2001 Dec 01; 15(23):3104-17.
View in:
PubMed
Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing. Cell Growth Differ. 2001 Sep; 12(9):447-55.
View in:
PubMed
p53 family update: p73 and p63 develop their own identities. Cell Growth Differ. 2001 Jul; 12(7):337-49.
View in:
PubMed
Differential control of transcription by DNA-bound cyclins. Mol Biol Cell. 2001 Jul; 12(7):2207-17.
View in:
PubMed
Human cytotrophoblast expression of the von Hippel-Lindau protein is downregulated during uterine invasion in situ and upregulated by hypoxia in vitro. Dev Biol. 2001 May 15; 233(2):526-36.
View in:
PubMed
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001 May 01; 10(10):1019-27.
View in:
PubMed
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001 Apr 20; 292(5516):464-8.
View in:
PubMed
The von Hippel-Lindau tumor suppressor gene. Exp Cell Res. 2001 Mar 10; 264(1):117-25.
View in:
PubMed
Role of the newer p53 family proteins in malignancy. Apoptosis. 2001 Feb-Apr; 6(1-2):17-29.
View in:
PubMed
The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev. 2001 Feb; 11(1):27-34.
View in:
PubMed
Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res. 2000 Dec 15; 60(24):6875-7.
View in:
PubMed
Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol Cell Biol. 2000 Dec; 20(23):8889-902.
View in:
PubMed
Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000 Dec; 6(12):1335-40.
View in:
PubMed
Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene. 2000 Nov 23; 19(50):5703-11.
View in:
PubMed
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature. 2000 Oct 05; 407(6804):642-5.
View in:
PubMed
Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 2000 Oct 05; 407(6804):645-8.
View in:
PubMed
Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev. 2000 Sep 01; 14(17):2185-91.
View in:
PubMed
Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000 Jul; 2(7):423-7.
View in:
PubMed
p63 and p73: old members of a new family. Biochim Biophys Acta. 2000 May 17; 1470(3):M93-M100.
View in:
PubMed
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000 May; 25(1):47-54.
View in:
PubMed
The p53 gene family. Oncogene. 1999 Dec 13; 18(53):7701-5.
View in:
PubMed
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest. 1999 Dec; 104(11):1583-91.
View in:
PubMed
Choosing anticancer drug targets in the postgenomic era. J Clin Invest. 1999 Dec; 104(11):1503-6.
View in:
PubMed
Taking aim at novel molecular targets in cancer therapy. J Clin Invest. 1999 Dec; 104(11):1495.
View in:
PubMed
Functions of the retinoblastoma protein. Bioessays. 1999 Nov; 21(11):950-8.
View in:
PubMed
RBP1 recruits both histone deacetylase-dependent and -independent repression activities to retinoblastoma family proteins. Mol Cell Biol. 1999 Oct; 19(10):6632-41.
View in:
PubMed
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol. 1999 Sep; 19(9):5902-12.
View in:
PubMed
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999 Jun 24; 399(6738):806-9.
View in:
PubMed
The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol Med Today. 1999 Jun; 5(6):257-63.
View in:
PubMed
Cancer. Many vessels, faulty gene. Nature. 1999 May 20; 399(6733):203-4.
View in:
PubMed
MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol. 1999 May; 19(5):3257-66.
View in:
PubMed
Third International Meeting on von Hippel-Lindau disease. Cancer Res. 1999 May 01; 59(9):2251-3.
View in:
PubMed
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 1999 Apr 23; 284(5414):657-61.
View in:
PubMed
Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999 Apr 16; 284(5413):455-61.
View in:
PubMed
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A. 1999 Apr 13; 96(8):4325-9.
View in:
PubMed
The emerging p53 gene family. J Natl Cancer Inst. 1999 Apr 07; 91(7):594-8.
View in:
PubMed
Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Mol Cell Biol. 1999 Feb; 19(2):1068-80.
View in:
PubMed
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 1998 Dec 15; 12(24):3872-81.
View in:
PubMed
Negative control elements of the cell cycle in human tumors. Curr Opin Cell Biol. 1998 Dec; 10(6):791-7.
View in:
PubMed
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res. 1998 Nov 01; 58(21):4957-62.
View in:
PubMed
Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol. 1998 Nov; 18(11):6316-24.
View in:
PubMed
The VHL tumour-suppressor gene paradigm. Trends Genet. 1998 Oct; 14(10):423-6.
View in:
PubMed
pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A. 1998 Sep 29; 95(20):11661-6.
View in:
PubMed
Another p53 Doppelgänger? Science. 1998 Jul 03; 281(5373):57-8.
View in:
PubMed
Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med. 1998 Jun; 243(6):535-9.
View in:
PubMed
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998 Jun; 1(7):959-68.
View in:
PubMed
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol. 1998 Feb; 18(2):732-41.
View in:
PubMed
Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev. 1998 Jan 01; 12(1):95-106.
View in:
PubMed
Alterations in G1/S cell-cycle control contributing to carcinogenesis. Ann N Y Acad Sci. 1997 Dec 29; 833:29-33.
View in:
PubMed
von Hippel-Lindau disease. Medicine (Baltimore). 1997 Nov; 76(6):381-91.
View in:
PubMed
Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol. 1997 Nov; 15(11):3301-12.
View in:
PubMed
Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997 Oct; 3(10):1145-9.
View in:
PubMed
p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997 Sep 11; 389(6647):191-4.
View in:
PubMed
The molecular basis of von Hippel-Lindau disease. Mol Med. 1997 May; 3(5):289-93.
View in:
PubMed
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol. 1997 Apr; 28(4):459-64.
View in:
PubMed
Fluorescence-activated cell sorting of transfected cells. Methods Enzymol. 1997; 283:59-72.
View in:
PubMed
Recent insights into the functions of the retinoblastoma susceptibility gene product. Cancer Invest. 1997; 15(3):243-54.
View in:
PubMed
Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol. 1996 Dec; 16(12):6623-33.
View in:
PubMed
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996 Oct 01; 93(20):10595-9.
View in:
PubMed
Structure and partial genomic sequence of the human E2F1 gene. Gene. 1996 Sep 16; 173(2):163-9.
View in:
PubMed
A maize cDNA encoding a member of the retinoblastoma protein family: involvement in endoreduplication. Proc Natl Acad Sci U S A. 1996 Aug 20; 93(17):8962-7.
View in:
PubMed
RB [corrected] as a modulator of transcription. Biochim Biophys Acta. 1996 Aug 08; 1288(1):M1-5.
View in:
PubMed
Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest. 1996 Aug; 75(2):231-8.
View in:
PubMed
A conserved region of unknown function participates in the recognition of E2F family members by the adenovirus E4 ORF 6/7 protein. Virology. 1996 Jun 01; 220(1):78-90.
View in:
PubMed
E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 1996 May 17; 85(4):549-61.
View in:
PubMed
The cellular effects of E2F overexpression. Curr Top Microbiol Immunol. 1996; 208:79-93.
View in:
PubMed
A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc Natl Acad Sci U S A. 1995 Dec 05; 92(25):11544-8.
View in:
PubMed
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 1995 Sep 08; 269(5229):1444-6.
View in:
PubMed
Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol. 1995 Aug; 15(8):4660.
View in:
PubMed
Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995 Aug; 1(8):822-6.
View in:
PubMed
Transcriptional control by E2F. Semin Cancer Biol. 1995 Apr; 6(2):99-108.
View in:
PubMed
The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol. 1995 Feb; 15(2):742-55.
View in:
PubMed
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A. 1994 Nov 08; 91(23):10918-22.
View in:
PubMed
Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol. 1994 Oct; 14(10):6607-15.
View in:
PubMed
Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell. 1994 Jul 15; 78(1):161-72.
View in:
PubMed
Cloning, chromosomal location, and characterization of mouse E2F1. Mol Cell Biol. 1994 Mar; 14(3):1861-9.
View in:
PubMed
Structural and functional contributions to the G1 blocking action of the retinoblastoma protein. (the 1992 Gordon Hamilton Fairley Memorial Lecture). Br J Cancer. 1993 Aug; 68(2):264-8.
View in:
PubMed
E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A. 1993 Aug 01; 90(15):6914-8.
View in:
PubMed
Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. Science. 1993 May 28; 260(5112):1330-5.
View in:
PubMed
A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol. 1993 Mar; 13(3):1610-8.
View in:
PubMed
Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell. 1992 Jul 24; 70(2):351-64.
View in:
PubMed
Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 1992 Jun; 6(6):953-64.
View in:
PubMed
Pyomyositis in patients with diabetes mellitus. Rev Infect Dis. 1991 Sep-Oct; 13(5):797-802.
View in:
PubMed
The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein. Cell. 1991 Jun 14; 65(6):1073-82.
View in:
PubMed
Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell. 1991 Feb 08; 64(3):521-32.
View in:
PubMed
RB associates with an E2F-like, sequence-specific DNA-binding protein. Cold Spring Harb Symp Quant Biol. 1991; 56:187-95.
View in:
PubMed
Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product. Mol Cell Biol. 1990 Jul; 10(7):3761-9.
View in:
PubMed
Systemic lupus erythematosus and myelofibrosis. Am J Med. 1986 Nov; 81(5):935-8.
View in:
PubMed
Lymphoscintigraphy. Eur J Nucl Med. 1985; 10(11-12):560-2.
View in:
PubMed
Blood flow to primary tumors and lymph node metastases in SMT-2A tumor-bearing rats following intravenous flunarizine. Cancer Res. 1984 Mar; 44(3):896-9.
View in:
PubMed
Microwave hyperthermia and its effect on tumor blood flow in rats. Cancer Res. 1983 Oct; 43(10):4665-9.
View in:
PubMed
Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats. Cancer Res. 1982 Oct; 42(10):3944-9.
View in:
PubMed
[Early diagnosis of cancer with capillary dynamic blood test]. Hippokrates. 1952 Sep 30; 23(18):495-501.
View in:
PubMed